US EditionPinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degraders in Oncology
- Pinetree Therapeutics raised $47 million in an oversubscribed Series B financing round to advance its oncology programs and AbReptor™ platform.
- The funds will support IND-enabling studies and Phase I clinical trials, expanding Pinetree's multispecific degrader portfolio.
- Pinetree's financing follows a July 2024 collaboration with AstraZeneca for an exclusive license on a preclinical EGFR degrader candidate.
- Pinetree aims to deliver novel targeted protein degraders to improve treatments for hard-to-treat cancers and other diseases.
51 Articles
51 Articles
Kingsport Times-News
Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degraders in Oncology
CAMBRIDGE, Mass., Oct. 28, 2025 /PRNewswire/ -- Pinetree Therapeutics, a preclinical-stage biotechnology company pioneering targeted protein degraders for drug-resistant cancers, announced the successful closing of an oversubscribed $47 million Series B financing. The proceeds will advance its lead preclinical oncology…
Pinetree Therapeutics Raises $47 Million Series B
Pinetree Therapeutics, a preclinical-stage biotechnology company pioneering targeted protein degraders for drug-resistant cancers, announced the successful closing of an oversubscribed $47 million Series B financing. The proceeds will advance its lead preclinical oncology programs to Phase I clinical studies and accelerate development of Pinetree’s AbReptor platform. Participating investors include existing investors DSC Investment, WIDWIN Inves…
Coverage Details
Bias Distribution
- 69% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
